Collaborators to develop ketamine treatments for mental health, chronic pain

Revitalist Lifestyle and Wellness Ltd. has announced a partnership with PharmaTher Holdings Ltd. to develop treatment protocols with ketamine for individuals with mental health disorders and chronic pain.

“Revitalist is unique in the sense that it is led by health care professionals who are resolute in bettering the current system,” Revitalist CEO Kathryn Walker said in a press release. “We understand the traditional legacy system and how it operates. We also understand the future system in terms of potential, research and outcomes.”

PharmaTher plans to engage Revitalist’s ketamine clinics for future clinical studies with KETARX, a specialty line of ketamine products. PharmaTher additionally plans to develop a ketamine microneedle patch for mental health and pain disorders, as well as a proprietary ketamine hydrochloride USP injection product to support pending phase 3 clinical studies for Parkinson’s disease and amyotrophic lateral sclerosis.